Anticoagulation for continuous arteriovenous hemofiltration in children.

Area of Science:

• Pediatric Nephrology
• Critical Care Medicine
• Cardiovascular Research

Background:

• Continuous arteriovenous hemofiltration (CAVH) is vital for fluid and electrolyte balance in critically ill children.
• Early hemofilter clotting necessitates continuous anticoagulation to ensure treatment efficacy and duration.
• Managing anticoagulation in pediatric patients, especially those with bleeding risks, presents unique challenges.

Purpose of the Study:

• To evaluate the efficacy and safety of heparin and prostacyclin as anticoagulants during pediatric CAVH.
• To determine the impact of different anticoagulation strategies on hemofilter lifespan.
• To assess the safety profile of these anticoagulants in high-risk pediatric populations.

Main Methods:

• Retrospective analysis of pediatric patients undergoing CAVH.
• Administration of continuous heparin infusion via the arterial line in patients with normal coagulation.
• Use of combined heparin and/or prostacyclin in patients with preexisting coagulopathy or high bleeding risk.

Main Results:

• Heparin infusion resulted in mean filter running times of 22.2 +/- 9.6 hours (0.1-m2 filter) and 26.6 +/- 4.7 hours (0.25-m2 filter).
• Combined heparin/prostacyclin infusion achieved a mean filter running time of 31 +/- 8.8 hours.
• Prostacyclin monotherapy was effective in only one patient with coagulopathy.
• No instances of bleeding, thrombosis, or hypotension were reported.

Conclusions:

• Continuous heparin anticoagulation is effective in prolonging hemofilter function in pediatric CAVH.
• Combination therapy with heparin and prostacyclin offers extended filter survival, particularly in high-risk patients.
• The evaluated anticoagulation strategies demonstrate a favorable safety profile in pediatric CAVH, with no significant adverse events observed.